Taysha Gene Therapies Stock Earnings Reports

Taysha Gene Therapies (Q1 2026) — Key points for investors:

- Regulatory: Recent Type B breakthrough meeting and a Type C meeting with FDA reaffirmed alignment on the BLA pathway for TSHA-102. FDA indicated the company may be able to pursue approval based on a 6-month interim analysis from the REVEAL pivotal trial, dependent on the totality of evidence. CMC comparability between clinical and commercial processes was acknowledged and a BLA-enabling PPQ campaign was initiated in April, expected to complete by Q4 2026.

- Clinical: Dosing progressed in the REVEAL pivotal (Part B) and ASPIRE trials, with completion of dosing expected in Q2 2026. Part A (Phase I/II) longer-term data (≥12 months for all 12 patients) will be reported later this quarter. To date (May 2026 cutoff) both high- and low-dose TSHA-102 have been generally well tolerated with no treatment-related serious adverse events or dose-limiting toxicities reported. Part A showed strong functional results (83% response at 6 months for first reported cohort; 100% response at 9 months in high-dose patients) and many additional functional gains per patient.

- Science/Delivery: Preclinical and newly published data support the use of a self-complementary AAV9 mini-MECP2 construct delivered via minimally invasive lumbar intrathecal administration, showing substantially higher transduction/protein expression vs. single-stranded AAV9 and comparable functional activity of the mini-MECP2. Intrathecal delivery is positioned as scalable and preferred by clinicians/caregivers vs. direct-to-brain approaches.

- Manufacturing/Commercial Readiness: PPQ campaign underway using commercial process at Catalent (Baltimore); facility has gene-therapy experience and is FDA-inspected. Taysha has begun building a commercial organization and will provide further commercial planning details in H2 2026.

- Financials / Runway: Q1 2026 net loss $42.4M vs. $21.5M prior year quarter. Cash and equivalents of $276.6M as of March 31, 2026; management expects cash to fund operations into 2028. R&D expense increase driven by PPQ and trial activity.

- Key investor considerations: FDA is open to a 6-month approval scenario but will judge on totality of evidence (including pooled Part A data and CMC comparability). Upcoming Part A ≥12-month data and the Part B 6-month interim readout are major near-term catalysts. Safety so far is favorable; commercial scalability via intrathecal delivery is a strategic differentiator.